149 related articles for article (PubMed ID: 22023897)
1. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?
Devogelaer JP; Boutsen Y; Gruson D; Manicourt D
Rheum Dis Clin North Am; 2011 Aug; 37(3):365-86, v-vi. PubMed ID: 22023897
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of bone health and osteoporosis risk.
Eastell R; Hannon RA
Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
[TBL] [Abstract][Full Text] [Related]
3. Is bone mineral density predictive of fracture risk reduction?
Cefalu CA
Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843
[TBL] [Abstract][Full Text] [Related]
4. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O
Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258
[TBL] [Abstract][Full Text] [Related]
5. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
Garnero P; Delmas PD
Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
[TBL] [Abstract][Full Text] [Related]
6. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.
Garnero P; Delmas PD
J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):50-63. PubMed ID: 15615078
[TBL] [Abstract][Full Text] [Related]
7. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
Bonnick SL; Shulman L
Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
9. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
10. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
11. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
13. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
14. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
Lyritis GP; Georgoulas T; Zafeiris CP
Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of bone quality. Bone quality and osteoporosis treatment].
Mashiba T
Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
[TBL] [Abstract][Full Text] [Related]
16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical markers of bone turnover: Serum P1NP].
Imanishi Y; Nishizawa Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():231-5. PubMed ID: 18161111
[No Abstract] [Full Text] [Related]
18. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
[TBL] [Abstract][Full Text] [Related]
19. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis.
Papapoulos S; Makras P
Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):514-23. PubMed ID: 18714329
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive approach to fragility fractures.
Rebolledo BJ; Unnanuntana A; Lane JM
J Orthop Trauma; 2011 Sep; 25(9):566-73. PubMed ID: 21654529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
